Abstract
Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.
Keywords: Diabetic macular edema, Proliferative diabetic retinopathy, Panretinal photocoagulation, Vascular endothelial, growth factor, Intravitreal bevacizumab
Current Diabetes Reviews
Title: Intravitreal Bevacizumab for Diabetic Retinopathy
Volume: 5 Issue: 1
Author(s): J. Fernando Arevalo and Rafael A. Garcia-Amaris
Affiliation:
Keywords: Diabetic macular edema, Proliferative diabetic retinopathy, Panretinal photocoagulation, Vascular endothelial, growth factor, Intravitreal bevacizumab
Abstract: Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab on DR including DME and PDR. The results indicate that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and visual acuity (VA), independent of the type of macular edema that is present. Therefore, in the future this new treatment modality could replace or complement focal/grid laser photocoagulation in DME. In addition, in PDR, this new option could be an adjuvant agent to PRP so that more selective therapy may be applied.
Export Options
About this article
Cite this article as:
Arevalo Fernando J. and Garcia-Amaris A. Rafael, Intravitreal Bevacizumab for Diabetic Retinopathy, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314121
DOI https://dx.doi.org/10.2174/157339909787314121 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry The Structural Alteration and Aggregation of Bovine Lens Gamma-Crystallin by Homocysteinylation; The Pathomechanism Underlying Cataract Development During Hyperhomocysteinimia
Protein & Peptide Letters Noninvasive Monitoring of Intracranial Pressure
Recent Patents on Biomedical Engineering (Discontinued) Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets Respiratory Hypoxia and Oxidative Stress in the Brain. Is the Endogenous Erythropoietin an Antioxidant?
Current Chemical Biology Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Diffusion of Macromolecule Through Retina After Experimental Branch Retinal Vein Occlusion and Estimate of Intraretinal Barrier
Current Drug Metabolism Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research